Penn’s one-stop solution for technology commercialization and entrepreneurship
I’m a Faculty Member or Researcher
I’m with a Company
I’m an Entrepreneur
I want to:
Translating Discoveries
PCI helps to translate discoveries and ideas created at the University of Pennsylvania into new products and businesses for societal benefit.
We actively facilitate a broad range of technology development connections between Penn and the private sector. Whether the end result is a technology license, an R&D alliance, or the formation of a new venture, PCI serves as a dedicated one-stop shop for commercial partnering with Penn.
Access the FY2025 Year in Review
#1
in licensing revenue 5th year in a row
26
Startups launched
>$591M
in investment capital raised or received by Penn affiliated startups
99
New patents awarded
Innovation Stories
Penn Faculty Receive ARPA-H Awards for Gene Therapy Research
The Advanced Research Projects Agency for Health (ARPA-H) awarded $43 million to Philadelphia gene therapy researchers to advance treatments for rare diseases. The recipients include:
- GEMMA Biotherapeutics, a Penn spinout co-founded by Jim Wilson, MD, PhD, emeritus professor in Penn Medicine, to develop gene therapies using AI.
- CHOP, to support a team led by Kiran Musunuru, MD, PhD, the Barry J. Gertz Professor for Translational Research at Penn Medicine, and Rebecca Ahrens-Nicklas, MD, PhD, Director of the Gene Therapy for Inherited Metabolic Disorders Frontier Program (GTIMD) at Children’s Hospital of Philadelphia, which is developing a platform for treating rare genetic, liver-related diseases in infants and children.
This funding will support the advancement and scaling of groundbreaking treatment opportunities for patients.
Learn MoreKira Pharmaceuticals to Merge with Jasper Therapeutics
The Advanced Research Projects Agency for Health (ARPA-H) awarded $43 million to Philadelphia gene therapy researchers to advance treatments for rare diseases. The recipients include:
Kira Pharmaceuticals announced its merger with Jasper Therapeutics, alongside $132 million in financing to advance biologic therapies for immune-mediated diseases.
Kira was co-founded by Wenchao Song, PhD, Professor of Systems Pharmacology and Translational Therapeutics at Penn Medicine, and has built a differentiated complement therapy portfolio that will strengthen the combined company’s pipeline of treatments and support development through the second half of 2028.
Learn More
Read the Latest News from PCI on LinkedIn
Available Technologies
Find technology opportunities by sector or search:
Nanotechnology | Antibody | Optics & Photonics | Medical Devices | COVID-19 | Immunology | Oncology | Materials | Bioengineering | Neurodegenerative Diseases
View all technologies
Upcoming Events
All Events